Hong Kong Professional Services Stock News

CNOOC (SEHK:883) just released its financial results for the first nine months of 2025, showing lower sales and net income compared to last year. This update comes shortly after recent leadership changes, drawing investor focus. See our latest analysis for CNOOC. Despite a dip in sales and net income this quarter, CNOOC’s share price has been building momentum, rising 3.5% over the past day and boasting a 1-year total shareholder return of 21%. Leadership changes and the earnings update...

IVD Medical Holding (SEHK:1931) has rolled out a pair of headline-grabbing initiatives. The company is developing the ivd.xyz Exchange, a real-world asset platform for medical innovative drugs, and moving forward with its IVDD stablecoin program. See our latest analysis for IVD Medical Holding. Behind the headlines, IVD Medical Holding’s share price has delivered remarkable momentum, with a 254.8% return year-to-date and a 280.6% total return over the past 12 months. While there has been a...

Tencent Holdings (SEHK:700) shares have seen some movement recently, sparking conversations about the company’s underlying value. Investors are taking a closer look at the stock’s performance and financial fundamentals as they head into the next quarter. See our latest analysis for Tencent Holdings. Tencent Holdings has enjoyed a strong run lately, with the share price returning nearly 51% for investors over the past year. Shorter-term momentum has cooled, following a solid three-year total...

As global markets navigate a complex landscape marked by mixed performances in major indices and shifting monetary policies, investors are closely watching for opportunities amid these fluctuations. The recent rate cuts by the Federal Reserve and the temporary trade truce between the U.S. and China have added layers of complexity to market dynamics, prompting a focus on stocks that may be undervalued relative to their estimated intrinsic value. In this environment, identifying undervalued...

Key Insights The considerable ownership by private companies in Yuexiu Property indicates that they collectively have a...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

As global markets navigate a complex landscape marked by mixed performances and geopolitical developments, Asia's stock markets present intriguing opportunities for investors. With Japan's record highs and China's cautious optimism amid trade discussions, identifying undervalued stocks becomes crucial in capitalizing on potential market inefficiencies. In this context, understanding the fundamentals that make a stock undervalued—such as strong financial health, growth potential, and favorable...

The Asian markets have been closely watched as global economic dynamics shift, with the recent U.S.-China trade truce providing a temporary boost to investor sentiment. In this context, penny stocks, though often overlooked, can present intriguing opportunities when they exhibit robust financial health. These smaller or newer companies hold potential for growth and value that larger firms might not offer, and we will explore three such compelling stocks in the Asian market.

As global markets navigate a complex landscape of interest rate adjustments and trade negotiations, Asian markets are also experiencing notable developments. With Japan's stock markets reaching record highs and China focusing on domestic demand to bolster growth, investors are increasingly interested in dividend stocks as a potential source of steady income amidst these shifting economic conditions. A good dividend stock often combines reliable payouts with the ability to adapt to evolving...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

While 3SBio Inc. ( HKG:1530 ) shareholders have enjoyed a good week with stock up 10%, they need remain vigilant. In...

The board of directors of Hansoh Pharmaceutical Group announced that China's National Medical Products Administration has accepted the New Drug Application for HS-10365 capsules, a selective RET inhibitor for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer. This regulatory milestone not only reflects progress in Hansoh’s oncology pipeline, but also highlights the company’s potential to address significant unmet needs in lung cancer...

Impro Precision Industries (SEHK:1286) just posted a strong year-on-year jump in third quarter revenue, with standout gains in its diversified industrials and AI-related segments. The company’s positive sales outlook continues to draw attention from investors. See our latest analysis for Impro Precision Industries. Momentum has clearly shifted in Impro Precision Industries’ favor, with the share price climbing 12.87% over the past month and surging 65% in the last quarter. That is part of a...

Key Insights Significant control over TUHU Car by individual investors implies that the general public has more power...

Those holding Magnus Concordia Group Limited ( HKG:1172 ) shares would be relieved that the share price has rebounded...

China Environmental Technology and Bioenergy Holdings Limited ( HKG:1237 ) shareholders won't be pleased to see that...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Crystal International Group's (HKG:2232) stock is up by a considerable 18% over the past three months. Since the market...

In recent announcements by CSPC Pharmaceutical Group, the company received approval to begin clinical trials for its innovative siRNA drug SYH2061 targeting complement component C5, and its co-developed HER2-targeting antibody-drug conjugate JSKN003 was granted Breakthrough Therapy Designation in China for advanced colorectal cancer. These regulatory milestones highlight CSPC’s expanding capabilities in developing first-in-class treatments addressing significant unmet clinical needs within...

Chery Automobile (SEHK:9973) has been trading in a relatively narrow range, with its share price closing at HK$32.38. Over the past month, the stock edged up by 1%, reflecting investors’ cautious optimism. See our latest analysis for Chery Automobile. Momentum has been fairly muted for Chery Automobile, as this year’s modest 1.4% share price return suggests investors are still waiting to see if recent progress translates into stronger growth. After a flurry of updates earlier in the year, the...

Ascletis Pharma (SEHK:1672) has drawn attention this week by selecting ASC36, a once-monthly amylin receptor agonist, as its next clinical candidate for obesity treatment. The company intends to submit an IND for ASC36 to the U.S. FDA in 2026. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s run of pipeline news, including the latest about ASC36, has helped fuel market momentum, even as recent weeks saw some volatility. After an incredible year-to-date share price return of...

Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like mazdutide and SINTBILO. See our latest analysis for Innovent Biologics. Innovent’s shares have been on a rollercoaster in recent weeks, but momentum is clearly building overall. The stock’s 1-year total shareholder return sits at an impressive 148%, even after some profit-taking since last month...

Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total...

Weichai Power Co., Ltd. reported earnings for the nine months ended September 30, 2025, posting sales of CNY 170.57 billion and net income of CNY 8.88 billion, both higher than the same period last year. The results showed an increase in both revenue and basic earnings per share from continuing operations, highlighting ongoing improvement in profitability and operational scale. With solid gains in sales and earnings, we'll examine how Weichai Power's consistent financial growth impacts its...